Cargando…
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis,...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901793/ https://www.ncbi.nlm.nih.gov/pubmed/20680104 |
_version_ | 1782183710209081344 |
---|---|
author | Fakih, M. Vincent, M. |
author_facet | Fakih, M. Vincent, M. |
author_sort | Fakih, M. |
collection | PubMed |
description | The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC. |
format | Text |
id | pubmed-2901793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-29017932010-08-02 Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer Fakih, M. Vincent, M. Curr Oncol Medical Oncology The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC. Multimed Inc. 2010-07 /pmc/articles/PMC2901793/ /pubmed/20680104 Text en 2010 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Medical Oncology Fakih, M. Vincent, M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title_full | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title_fullStr | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title_full_unstemmed | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title_short | Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer |
title_sort | adverse events associated with anti-egfr therapies for the treatment of metastatic colorectal cancer |
topic | Medical Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901793/ https://www.ncbi.nlm.nih.gov/pubmed/20680104 |
work_keys_str_mv | AT fakihm adverseeventsassociatedwithantiegfrtherapiesforthetreatmentofmetastaticcolorectalcancer AT vincentm adverseeventsassociatedwithantiegfrtherapiesforthetreatmentofmetastaticcolorectalcancer |